Travis T Wager

List of Publications by Year
in descending order

40 papers	4,329 citations	186265 28 h-index	289244 40 g-index
40 all docs	40 docs citations	40 times ranked	5444 citing authors

#	Article	IF	Citations
1	Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chemical Neuroscience, 2010, 1, 435-449.	3.5	763
2	Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4872-4875.	2.2	749
3	Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes. ACS Chemical Neuroscience, 2010, 1, 420-434.	3.5	381
4	Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery. ACS Chemical Neuroscience, 2016, 7, 767-775.	3.5	338
5	Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15240-15245.	7.1	219
6	Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand. Journal of Medicinal Chemistry, 2013, 56, 4568-4579.	6.4	172
7	Selective Inhibition of Casein Kinase 1Ïµ Minimally Alters Circadian Clock Period. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 430-439.	2.5	157
8	Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 419-432.	6.4	147
9	Physicochemical drug properties associated within vivotoxicological outcomes: a review. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 921-931.	3.3	131
10	Reductive cleavage of Nî—¸O bonds in hydroxylamine and hydroxamic acid derivatives using SmI2/THF. Tetrahedron Letters, 1995, 36, 7419-7422.	1.4	120
11	Reductive cleavage of Nî—¸O bonds in hydroxylamines and hydroxamic acid derivatives using samarium diiodide. Tetrahedron, 1999, 55, 11755-11772.	1.9	104
12	Total Syntheses of (â^')-Lycoricidine, (+)-Lycoricidine, and (+)-Narciclasine via 6-exoCyclizations of Substituted Vinyl Radicals with Oxime Ethersâ€. Journal of the American Chemical Society, 1999, 121, 5176-5190.	13.7	90
13	An Especially Convenient Stereoselective Reduction of Î²-Hydroxy Ketones to Anti 1,3 Diols Using Samarium Diiodideâ€. Journal of Organic Chemistry, 1999, 64, 2172-2173.	3.2	81
14	Discovery of Two Clinical Histamine H₃Receptor Antagonists:trans-N-Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) andtrans-3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764). Journal of Medicinal Chemistry, 2011, 54, 7602-7620.	6.4	80
15	Total Synthesis ofent-Lycoricidineviaa Thiyl Radical Additionâ^'Cyclization Sequenceâ€. Journal of Organic Chemistry, 1996, 61, 8366-8367.	3.2	65
16	Csnk1e Is a Genetic Regulator of Sensitivity to Psychostimulants and Opioids. Neuropsychopharmacology, 2012, 37, 1026-1035.	5.4	60
17	Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability. Journal of Medicinal Chemistry, 2016, 59, 5284-5296.	6.4	57
18	A Second-Generation Radical-Based Synthesis of (+)-7-Deoxypancratistatin. Journal of Organic Chemistry, 1998, 63, 9164-9165.	3.2	56

#	Article	IF	Citations
19	A Direct and Mild Conversion of Tertiary Aryl Amides to Methyl Esters Using Trimethyloxonium Tetrafluoroborate: A Very Useful Complement to Directed Metalation Reactions. Tetrahedron, 2000, 56, 9875-9883.	1.9	48
20	Strategies to optimize the brain availability of central nervous system drug candidates. Expert Opinion on Drug Discovery, 2011, 6, 371-381.	5.0	48
21	A Novel Mechanism Controlling Resetting Speed of the Circadian Clock to Environmental Stimuli. Current Biology, 2014, 24, 766-773.	3.9	46
22	Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration. Journal of Pharmaceutical Sciences, 2019, 108, 2476-2483.	3.3	46
23	Improving the Odds of Success in Drug Discovery: Choosing the Best Compounds for in Vivo Toxicology Studies. Journal of Medicinal Chemistry, 2013, 56, 9771-9779.	6.4	41
24	Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing. Journal of the American Chemical Society, 2020, 142, 8706-8727.	13.7	39
25	Strategies to minimize CNS toxicity:in vitrohigh-throughput assays and computational modeling. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 531-542.	3.3	33
26	In Vitroâ€“In Vivo Extrapolation of Key Transporter Activity at the Bloodâ€“Brain Barrier. Drug Metabolism and Disposition, 2019, 47, 405-411.	3.3	32
27	Late-Stage Microsomal Oxidation Reduces Drugâ€“Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189. ACS Medicinal Chemistry Letters, 2018, 9, 68-72.	2.8	31
28	Casein Kinase 1Î´/Îµ Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior. ACS Chemical Neuroscience, 2014, 5, 1253-1265.	3.5	29
29	Systems approach reveals photosensitivity and <scp>PER</scp> 2 level as determinants of clockâ€modulator efficacy. Molecular Systems Biology, 2019, 15, e8838.	7.2	29
30	Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4132-4140.	2.2	26
31	A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugsâ€”From phenobarbital to cenobamate and beyond. Epilepsia, 2020, 61, 1543-1552.	5.1	26
32	Ligandâ€“Protein Interactions of Selective Casein Kinase 1Î´ Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 6819-6828.	6.4	25
33	Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors. ACS Chemical Neuroscience, 2017, 8, 1995-2004.	3.5	21
34	Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects. ACS Chemical Neuroscience, 2017, 8, 165-177.	3.5	17
35	Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting. ACS Chemical Neuroscience, 2021, 12, 1007-1017.	3.5	6
36	Synthesis of (+)-(R)-6-Ethyl-2,3-dihydro-2-methyl-4Hpyran-4-one -Sex-Pheromone Component of the Male Swift MothHepialus hectaL. Synthetic Communications, 1993, 23, 87-95.	2.1	4

#	Article	IF	Citations
37	The Scientist-in-Residence Program: A Chemistry-Based Outreach Initiative. Journal of Chemical Education, 1994, 71, 864.	2.3	4
38	Glycogen Synthase Kinase-3 (GSK-3): A Kinase with Exceptional Therapeutic Potential. Annual Reports in Medicinal Chemistry, 2005, 40, 135-147.	0.9	3
39	Central Modulation of Circadian Rhythm via CK1 Inhibition for Psychiatric Indications. Annual Reports in Medicinal Chemistry, 2011, 46, 33-51.	0.9	3
40	Getting the MAX out of Computational Models: The Prediction of Unbound-Brain and Unbound-Plasma Maximum Concentrations. ACS Medicinal Chemistry Letters, 2012, 3, 515-519.	2.8	2